Iovance Boosts 2026 Revenue Forecast by 15% on Strong U.S. Demand…

Event summary

Iovance raised its 2026 revenue guidance to $410–$420M, up $55M from prior $350–$370M range.
Strong U.S. demand for Amtagvi and Proleukin drove the 15% midpoint increase.
Q2 2026 product revenue hit $99.3M, with ATC network expanding to ~100 centers.
Company expects to reach 110 ATCs by year-end 2026.
Lifileucel advancing in registrational programs for new solid tumor indications.

The big picture

Iovance's upgraded guidance reflects strong execution in the U.S. oncology market, where TIL therapies are gaining traction. The company's ability to scale manufacturing and expand its ATC network will be critical in sustaining this momentum amid competitive pressures in cell therapy. With nearly 60% annual revenue growth, Iovance is positioning itself as a key player in the solid tumor treatment space.

What we're watching

Commercial Momentum: Whether sustained demand for Amtagvi and Proleukin can maintain 60% annual revenue growth.
Manufacturing Scale: The pace at which Iovance can expand manufacturing to meet increasing patient demand.
Pipeline Progress: How advancements in lifileucel's registrational programs will impact long-term market positioning.